Preclinical News and Research

RSS

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.

2 Jul 2014

Researchers receive over $1M to study molecular foundations of pancreatic cancer

Alexandros Tzatsos, M.D., Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, was awarded over one million dollars in grants from the National Institutes of Health to study the molecular foundations of pancreatic cancer.

1 Jul 2014

Researchers identify new protein as possible therapeutic target for pancreatic cancer

Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer.

1 Jul 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Non-surgical gum disease treatment reduces thickness of wall of arteries

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

28 Jun 2014

Cancer drug shows promise in treating blood cell disorders

Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell's natural defenses and efficiently insert disease-fighting genes into the cell's genome.

27 Jun 2014

Jackson Laboratory Cancer Center earns renewal of Cancer Center Support Grant from NCI

The Jackson Laboratory Cancer Center has once again earned the renewal of its Cancer Center Support Grant from the National Cancer Institute (NCI).

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).

25 Jun 2014

University of Maryland School of Medicine receives NIH grant to establish neuroscience research center

The University of Maryland School of Medicine's Maryland Psychiatric Research Center, a research center in the School's Department of Psychiatry, was awarded a $10.7 million grant from the National Institutes of Health to establish a Silvio O. Conte Neuroscience Research Center that will examine the causes of schizophrenia and search for possible new treatments.

25 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

Researchers shown how free radicals contribute to fatty liver disease

An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease.

23 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

23 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

According the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood.

20 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

Preclinical News and Research

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Researchers receive over $1M to study molecular foundations of pancreatic cancer

Researchers identify new protein as possible therapeutic target for pancreatic cancer

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Non-surgical gum disease treatment reduces thickness of wall of arteries

Cancer drug shows promise in treating blood cell disorders

Jackson Laboratory Cancer Center earns renewal of Cancer Center Support Grant from NCI

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

University of Maryland School of Medicine receives NIH grant to establish neuroscience research center

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Researchers shown how free radicals contribute to fatty liver disease

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics